| No. of Pts | Pre-SUV * | Post-SUV * | ΔSUV% * | HPR (%) |
---|---|---|---|---|---|
ER | Â | Â | Â | Â | Â |
   Positive | 38 | 6.4 ± 3.3 | 3.7 ± 2.1 | 30 ± 57 | 3 (7.9) |
   Negative | 40 | 8.6 ± 4.9 | 4.1 ± 3.1 | 48 ± 37 | 11 (27.5) |
 |  | P = 0.047 | P = 0.936 | P = 0.038 | P = 0.037†|
PR | Â | Â | Â | Â | Â |
   Positive | 30 | 6.5 ± 3.3 | 3.5 ± 2.4 | 36 ± 63 | 3 (10.0) |
   Negative | 48 | 8.2 ± 4.8 | 4.2 ± 2.8 | 42 ± 37 | 11 (22.9) |
 |  | P = 0.187 | P = 0.347 | P = 0.837 | P = 0.226†|
HER2 | Â | Â | Â | Â | Â |
   Positive | 17 | 6.8 ± 3.2 | 3.2 ± 2.6 | 51 ± 36 | 5 (29.4%) |
   Negative | 61 | 7.7 ± 4.6 | 4.1 ± 2.7 | 36 ± 51 | 9 (14.8%) |
 |  | P = 0.818 | P = 0.247 | P = 0.189 | P = 0.164†|
Triple negativity | Â | Â | Â | Â | Â |
   TNBC | 26 | 9.8 ± 5.3 | 5.0 ± 3.0 | 42 ± 35 | 6 (23.1) |
   Non-TNBC | 52 | 6.4 ± 3.2 | 3.4 ± 2.3 | 38 ± 54 | 8 (15.4) |
 |  | P = 0.008 | P = 0.076 | P = 0.799 | P = 0.404†|
Molecular phenotype | Â | Â | Â | Â | Â |
   Luminal A/B | 40 | 6.3 ± 3.3 | 3.6 ± 2.2 | 33 ± 57 | 3 (7.5) |
   HER2 | 12 | 6.6 ± 3.2 | 2.8 ± 2.6 | 56 ± 39 | 5 (41.7) |
   TNBC | 26 | 9.8 ± 5.3 | 5.0 ± 3.0 | 42 ± 35 | 6 (23.1) |
 |  | P = 0.016‡ | P = 0.055‡ | P = 0.150‡ | P = 0.018†|
Ki-67 | Â | Â | Â | Â | Â |
   Low expression§ | 30 | 6.2 ± 4.1 | 3.6 ± 2.6 | 27 ± 65 | 4 (13.3) |
   High expression | 41 | 8.5 ± 4.4 | 4.0 ± 2.8 | 49 ± 33 | 10 (24.4) |
 |  | P = 0.018 | P = 0.541 | P = 0.052 | P = 0.367†|